ERBB2 and breast carcinoma: In patients with luminal B breast cancer, compared with patients in the HER2+ subgroup, the median PFS of the HER2− subgroup was longer (19.1:15.1 months), and this difference was statistically significant (P = 0.042), as shown in Figure 4.